Clinical trials: PET-CT
Neuroendocrine Tumors
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
- Trial name
- NCT03278275
- Testing
- One injection of 68Ga-NOTA-AE105, PET/CT
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Primary Hyperparathyroidism
Diagnostic Performance of [11C]Choline PET/CT In the Preoperative Assessment of Primary Hyperparathyroidism
Primary hyperparathyroidism (HPT) ranks as the third most common endocrine disorder, characterized by excessive secretion of parathormone (PTH), a hormone crucial for regulating calcium and phosphorus metabolism within the body.
- Trial name
- NCT06647966
- Testing
- PET/CT
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
Correlation Between PET/CT Parameters and Tumor Markers in Recurrent Breast Cancer
Worldwide, breast cancer (BC) is the most frequent type of cancer in women yet, it is associated with relatively lower mortality rates, as it ranks fifth in cancer-related deaths overall, which is attributed to evolution in the…
- Trial name
- NCT05064475
- Testing
- PET/CT
- Volunteers
- 72 people
- Sponsor
- Assiut University
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial.
- Trial name
- NCT04989959
- Testing
- [18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Orhan Kemal Oz
Pancreatic Cancer, Breast Cancer
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
- Conditions
- Pancreatic Cancer, Breast Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05394259
- Testing
- Piflufolastat F18
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer
This study uses FES PET/CT imaging to evaluate estrogen receptor-positive breast cancer. FES PET/CT is a type of imaging that can show whether breast cancer cells have estrogen receptors.
- Trial name
- NCT07859046
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hunan Cancer Hospital
Lung Adenocarcinoma, Radiomics
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting the grade 3 tumors based on the novel grading system in clinical stage stage I lung adenocarcinoma based on a…
- Conditions
- Lung Adenocarcinoma, Radiomics, Grading System
- Trial name
- NCT05736991
- Testing
- PET/CT-based Radiomics Signature
- Where
- 4 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer Female, Breast Neoplasms
Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.
Examination of the feasibility of intra-operative pet CT to detect surgical margins in breast conservative surgery to prevent re-excision.
- Trial name
- NCT04343079
- Testing
- PET CT
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Osteosarcoma
Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients
The purpose of this study is to develop indices predicting response to pre-operative chemotherapy in osteosarcoma patients. Histologic response to pre-operative chemotherapy is very important for the ultimate outcome of…
- Trial name
- NCT00686738
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- National Cancer Center, Korea
Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
The investigators will test the hypothesis that positron emission tomography (PET) imaging with the imaging agent 18F-thymidine (FLT) can rapidly assess treatment response in patients with unresectable non-small cell lung cancer…
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Trial name
- NCT02274038
- Testing
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Prostate Cancer, Oligo-metastatic Prostate Carcinoma
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative…
- Conditions
- Prostate Cancer, Oligo-metastatic Prostate Carcinoma, Oligometastatic Cancer, Nodal Oligorecurrent Prostate Cancer
- Trial name
- PINPOINT (NCT07635108)
- Testing
- Single-fraction SBRT
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Odense University Hospital
Head and Neck Cancer
Imaging With a PET Agent for Detection of Cancers of the Head and Neck
The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people.
- Trial name
- NCT03631017
- Testing
- [18F]- PARPi, PET/CT Scans
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC
This multicenter retrospective study aims to investigate the value of 18F-FDG PET/CT radiomics features in the preoperative precision staging, pathological typing, gene mutation status prediction, and prognostic risk…
- Trial name
- PET-Rad-NSCLC (NCT07449858)
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rheumatoid Arthritis, Psoriatic Arthritis
PBR28 PET and Inflammatory Arthritis
The importance of the detection of early inflammatory arthritis is recognised as being essential to the prevention of permanent joint damage.
- Trial name
- NCT02361385
- Testing
- this is not an interventional study
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Oxford
Glioma
68Ga-NOTA-RM26 PET/CT in Glioma Patients
The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma…
- Trial name
- NCT06412952
- Testing
- 68Ga-RM26
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors.
- Conditions
- Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm
- Trial name
- NCT03001349
- Testing
- Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics
The purpose of this research study is to learn if differences seen in scans before surgery match differences seen when looking at tumor samples with pathology and genetic tests.
- Trial name
- NCT02144311
- Testing
- PET/CT Scan, MRI
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fertility
Secretory Azoospermia and FDG (Fluoro Deoxyglucose) PET-CT
Compare FDG PET-CT parameters between azoospermia patients having an extraction of sperm cells by positive testicular extraction and those with a negative extraction.
- Trial name
- AzoPredHisto (NCT02043444)
- Testing
- FDG PET-CT
- Where
- 5 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
PSMA PET/CT for Prostate Cancer
Prostate cancer is the most frequently occurring male cancer in Belgium. Patients who have been treated for prostate cancer, i.e.
- Trial name
- NGP2 (NCT03573011)
- Testing
- [18F]PSMA-11
- Where
- Belgium
- Volunteers
- 64 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer, Pancreatic Cancer
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer
The purpose of the study is to determine whether positron emission tomography (PET), using the new imaging drug [124 I] PSCA-Minibody can be used for imaging prostate, pancreatic or bladder cancer that has spread to the bones and…
- Conditions
- Prostate Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT02092948
- Testing
- [124I] PSCA-Minibody PET/CT imaging of the whole body
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.